This week on Fat Science, Dr. Emily Cooper, Andrea Taylor, and Mark Wright break down the latest science behind GLP-1 medications like Ozempic, Wegovy, and Mounjaro. Dr. Cooper shares her decades of expertise on how these drugs work, their evolution, and whether you really have to take them for life.
The episode dives deep into the individual factors that impact tapering off, the importance of metabolic signals (like famine and security signals), and why medication is just one piece of the metabolic puzzle.
Key Takeaways:
- GLP-1 medications have advanced significantly, with more convenient dosing and greater effectiveness for many—but responses vary widely from patient to patient.
- Weight on the scale isn’t the only measure; body composition, nutrient levels, and metabolic markers are critical in determining treatment and possible tapering.
- Not everyone needs to take GLP-1s forever—tapering is possible, but it depends on individual health markers, genetics, and whether metabolic signals are balanced.
- The future of metabolic health lies in combination therapies that target multiple pathways, not just GLP-1s.
- Dieting alone disrupts metabolic signals, making professional metabolic medicine and nutrition guidance essential for long-term health.
Resources:
Fat Science is a podcast on a mission to explain where our fat really comes from and why it won’t go and stay away. We are committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isn’t a failure. This podcast is for informational purposes only and is not intended to replace professional medical advice.
If you have a question for Dr. Cooper, a show idea, feedback, or just want to connect, email us at info@diabesityinstitute.org or dr.c@fatsciencepodcast.com.
Science is supported by the non-profit Diabesity Institute which is on a mission to increase access to effective, science-based medical care for those suffering from or at risk for diabesity. https://diabesityresearchfoundation.org/
